Table 1.
Clinical data, imaging abnormalities, and SSTR 2 expression
| Clinical data | Imaging abnormalities | SSTR 2 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt no | Age/sex | Stage | Previous therapy | Gr | Dg | PFS (months) | OS (months) | Follow-up (months) | V T1-Gad (cm 3 ) | DOTA | SUVmax | BP | C | H | L |
| 1 | 49/F | Primary | III | A | 29.4 | 0.57 | TOC | 0.79 | −0.26 | 0 | 2 | B | |||
| 2 | 62/F | Primary | III | A | 14.4 | 1.71 | NOC | 1.22b | NA | 0 | 2 | B | |||
| 3 | 44/F | Primary | III | A | 21.0 | 0 | NOC | −c | − | 1 | 3 | B | |||
| 4 | 49/M | Primary | III | A | 13.0 | 0 | NOC | − | − | 3 | 3 | C | |||
| 5 | 57/F | Primary | III | A | 10.4 | 12.5 | 0.16 | NOC | 0.69 | −0.47 | 0 | 0 | − | ||
| 6 | 18/M | Primary | III | A | 10.9 | 11.8 | 0 | NOC | − | − | 0 | 3 | B | ||
| 7 | 49/F | Primary | III | A | 10.7 | 0.81 | NOC | 0.69 d | NA | 1 | 3 | C | |||
| 8 | 32/F | Primary | III | A | 8.4 | 13.8 | 0 | X | X | X | 0 | 1 | C | ||
| 9 | 54/F | Primary | III | O | 13.6 | 27.7 | 0.03 | NOC | − | − | 3 | 3 | B | ||
| 10 | 60/M | Primary | III | OA | 21.6 | 0 | NOC | − | − | 3 | 3 | B | |||
| 11 | 71/M | Primary | IV | GBMO | 0 | 1.2 | 1.91 | NOC | 3.07 | 1.41 | 0 | 3 | M | ||
| 12 | 37/M | Primary | IV | GBMO | 21.0 | 4.32 | NOC | 0.99 | −0.62 | 3 | 3 | B | |||
| 13 | 35/F | Primary | IV | GBM | 0 | 13.7 | 1.27 | TOC | 0.65 | 0.39 | 0 | 1 | C | ||
| 14 | 63/F | Primary | IV | GBM | 24.0 | 24.1 | 12.2 | NOC | 2.21 | 0.98 | 0 | 0 | − | ||
| 15 | 62/F | Primary | IV | GBM | 0 | 7.3 | 11.5 | NOC | 3.01 | 1.26 | 0 | 0 | − | ||
| 16 | 67/F | Primary | IV | GBM | 0 | 4.4 | 14.8 | NOC | 1.62 | 0.36 | 0 | 1 | B | ||
| 17 | 70/M | Primary | IV | GBM | 0 | 1.0 | 21.5 | NOC | 2.85 | 1.80 | 0 | 3 | M | ||
| 18 | 76/F | Primary | IV | GS | 0 | 0.9 | 34.7 | NOC | 3.73 | 1.75 | 0 | 3 | M | ||
| 19 | 28/M | Recurrent | S | III | A | 81.2 | 106.1 | 0 | NOC | − | − | 1 | 3 | B | |
| 20 | 51/M | Recurrent | S, RT | III | O | 60.9 | 253.7 | 0 | NOC | − | − | 3 | 3 | B | |
| 21 | 42/F | Recurrent | S, S, RT, S | III | OA | 24.3 | 99.5 | 0 | NOC | − | − | 3 | 3 | C | |
| 22 | 46/M | Recurrent | S, RT, C | III | OA | 39.0 | 100.4 | 28.2 | NOC | 5.68 | 3.33 | 1 | 1 | C | |
| 23 | 42/F | Recurrent | S, CRT | IV | GBM | 24.0 | 37.1 | 0.04 | TOC | 0.46 | −0.34 | 0 | 3 | B | |
| 24 | 68/F | Recurrent | S, CRT | IV | GBM | 23.1 | 26.3 | 27.9 | NOC | 2.40 | 1.57 | 0 | 0 | − | |
| 25 | 64/F | Recurrent | S, CRT | IV | GBM | 34.2 | 38.2 | 12.8 | NOC | 2.70 | 1.07 | 0 | 3 | B | |
| 26 | 42/F | Recurrent | S, CRT | IV | GBM | 5.5 | 13.6 | 28.0 | NOC | 2.44 | 2.28 | 0 | 3 | B | |
| 27 | 61/F | Recurrent | S, RT | IV | sGBM | 16.1 | 21.3 | 2.59 | NOC | 1.98 | 0.64 | 0 | 2 | C | |
| 28 | 57/M | Recurrent | S, CRT | IV | GBM | 11.0 | 27.5 | 3.03a | NOC | 3.26 | 2.33 | 0 | 3 | B | |
Pt no, patient number; F, female; M, male; Gr, grade; Dg, diagnosis; A, astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; GBMO, glioblastoma with oligodendroglioma component; GBM, glioblastoma; sGBM, secondary GBM; GS, gliosarcoma; S, surgery; RT, radiotherapy; C, chemotherapy (temozolomide); CRT, chemoradiotherapy with adjuvant temozolomide; Dx, dexamethasone; TOC, 68Ga-DOTATOC; NOC, 68Ga-DOTANOC; −, no tracer uptake; X, no PET performed; NA, not applicable; C, intensity of most common staining (0 to 3); H, highest staining intensity (0 to 3); L, location of staining; C, cytoplasmic; M, membranous; B, both. aNo MRI (cardiac pacemaker), tumor volume defined from contrast-enhanced CT; bstatic PET 28 to 58 min post-injection (mild claustrophobia); cdynamic PET discontinued at 53 min post-injection (dyspnea); ddynamic PET discontinued at 36 min post-injection (numbness of the arm).